Oppenheimer Asset Management Inc. Has $18.49 Million Position in Medpace Holdings, Inc. $MEDP

Oppenheimer Asset Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,957 shares of the company’s stock after selling 1,743 shares during the period. Oppenheimer Asset Management Inc. owned approximately 0.13% of Medpace worth $18,488,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Quent Capital LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $25,000. Root Financial Partners LLC bought a new stake in Medpace in the 3rd quarter valued at $38,000. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares during the period. Finally, Employees Retirement System of Texas bought a new position in Medpace during the 2nd quarter worth about $36,000. 77.98% of the stock is owned by institutional investors.

Medpace Stock Down 2.2%

MEDP stock opened at $530.35 on Tuesday. The company has a market cap of $14.94 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 1.82 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The business has a 50 day moving average price of $578.30 and a two-hundred day moving average price of $539.57.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 302,192 shares of company stock valued at $182,019,762. Insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MEDP. Barclays lifted their price target on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Mizuho set a $660.00 price target on Medpace in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.